Randomized placebo-controlled trial of oral tannin supplementation on COVID-19 symptoms, gut dysbiosis and cytokine response
Metadatos
Mostrar el registro completo del ítemAutor
Molino, SilviaEditorial
Elsevier
Materia
COVID-19 Tannins Gut microbiota Dysbiosis Serum cytokines
Fecha
2022-11-30Referencia bibliográfica
Silvia Molino... [et al.]. Randomized placebo-controlled trial of oral tannin supplementation on COVID-19 symptoms, gut dysbiosis and cytokine response, Journal of Functional Foods, Volume 99, 2022, 105356, ISSN 1756-4646, [https://doi.org/10.1016/j.jff.2022.105356]
Patrocinador
Silvateam/Indunor SA; United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIDDK P30-DK56338 NIAID U01-AI24290 P01-AI152999Resumen
The clinical study aim was to investigate whether a tannin-based dietary supplementation could improve the
efficacy of standard-of-care treatment of hospitalized COVID-19 patients by restoring gut microbiota function.
Adverse events and immunomodulation post-tannin supplementation were also investigated. A total of 124
patients receiving standard-of-care treatment were randomized to oral tannin-based supplement or placebo for a
total of 14 days. Longitudinal blood and stool samples were collected for cytokine and 16S rDNA microbiome
profiling, and results were compared with 53 healthy controls. Although oral tannin supplementation did not
result in clinical improvement or significant gut microbiome shifts after 14-days, a reduction in the inflammatory
state was evident and significantly correlated with microbiota modulation. Among cytokines measured, MIP-1α
was significantly decreased with tannin treatment (p = 0.03) where it correlated positively with IL-1β and TNF-
α, and negatively with stool Bifidobacterium abundance.